Officials from drugmaker GlaxoSmithKline on Sunday announced that the company will file for Food and Drug Administration approval of its second-generation protease inhibitor, known as 908, by the end of the year. Developed jointly with Vertex Pharmaceuticals, 908 has been shown in clinical trials to reduce HIV viral loads to undetectable levels in about 70% of previously untreated HIV-positive adults with advanced HIV disease. Glaxo hopes to have the drug approved for marketing in the United States by the second half of 2003. The company also plans to file for regulatory approval in Europe and hopes to begin selling the drug there by early 2004.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes
These are some of his worst comments about LGBTQ+ people made by Charlie Kirk.